Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib

References

• SwerdlowSHCampoEPileriSThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood2016127202375239026980727
   PubMed Web of Science ®Google Scholar
• Al-HamadaniMHabermannTMCerhanJRMaconWRMaurerMJGoRSNon-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011Am J Hematol201590979079526096944
   PubMed Web of Science ®Google Scholar
• WeillJCWellerSReynaudCAHuman marginal zone B cellsAnnu Rev Immunol20092726728519302041
   PubMed Web of Science ®Google Scholar
• QuinnERChanCHHadlockKGFoungSKFlintMLevySThe B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesisBlood200198133745374911739181
   PubMed Web of Science ®Google Scholar
• ZuccaEBertoniFRoggeroEMolecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomachN Engl J Med1998338128048109504941
   PubMed Web of Science ®Google Scholar
• ZuccaEBertoniFVannataBCavalliFEmerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomasClin Cancer Res 4202052075216
   PubMed Web of Science ®Google Scholar
• KuoSHChengALHelicobacter pylori and mucosa-associated lymphoid tissue: what’s newHematology Am Soc Hematol Educ Program2013201310911724319171
   PubMedGoogle Scholar
• KhalilMOMortonLMDevesaSSIncidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic siteBr J Haematol20141651677724417667
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2014)National Cancer Institute D, Surveillance Research Program released April 2017, based on the November 2016 submission
   Google Scholar
• OlszewskiAJCastilloJJSurvival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results databaseCancer2013119362963822893605
   PubMed Web of Science ®Google Scholar
• NiemannCUWiestnerAB-cell receptor signaling as a driver of lymphoma development and evolutionSemin Cancer Biol201323641042124060900
   PubMed Web of Science ®Google Scholar
• NoyAde VosSThieblemontCTargeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphomaBlood2017129162224223228167659
   PubMed Web of Science ®Google Scholar
• YanQHuangYWatkinsAJBCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomasHaematologica201297459559822102703
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification ProjectBlood19978911390939189166827
   PubMed Web of Science ®Google Scholar
• CohenSMPetrykMVarmaMKozuchPSAmesEDGrossbardMLNon-Hodgkin’s lymphoma of mucosa-associated lymphoid tissueOncologist200611101100111717110630
   PubMed Web of Science ®Google Scholar
• DierlammJBaensMWlodarskaIThe apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomasBlood199993113601360910339464
   PubMed Web of Science ®Google Scholar
• WillisTGJadayelDMDuMQBcl10 is involved in t(1;14) (p22;q32) of MALT B cell lymphoma and mutated in multiple tumor typesCell199996135459989495
   PubMed Web of Science ®Google Scholar
• StreubelBLamprechtADierlammJT(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphomaBlood200310162335233912406890
   PubMed Web of Science ®Google Scholar
• RinaldiAMianMChigrinovaEGenome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcomeBlood201111751595160421115979
   PubMed Web of Science ®Google Scholar
• KweeIRancoitaPMRinaldiAGenomic profiles of MALT lymphomas: variability across anatomical sitesHaematologica20119671064106621459788
   PubMed Web of Science ®Google Scholar
• SuarezFLortholaryOHermineOLecuitMInfection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferationBlood200610783034304416397126
   PubMed Web of Science ®Google Scholar
• O’RourkeJLGene expression profiling in Helicobacter-induced MALT lymphoma with reference to antigen drive and protective immunizationJ Gastroenterol Hepatol200823Suppl 2S151S15619120889
   PubMedGoogle Scholar
• BracciPMBenaventeYTurnerJJMedical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectJ Natl Cancer Inst Monogr2014201448526525174026
   PubMedGoogle Scholar
• ArcainiLBurcheriSRossiAPrevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALTAnn Oncol200718234635017071937
   PubMed Web of Science ®Google Scholar
• ArcainiLMerliMVolpettiSRattottiSGottiMZajaFIndolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapyClin Dev Immunol2012201263818522956970
   PubMed Web of Science ®Google Scholar
• HermineOLefrèreFBronowickiJPRegression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infectionN Engl J Med20023472899412110736
   PubMed Web of Science ®Google Scholar
• DerringerGAThompsonLDFrommeltRABijwaardKEHeffessCSAbbondanzoSLMalignant lymphoma of the thyroid gland: a clinicopathologic study of 108 casesAm J Surg Pathol200024562363910800981
   PubMed Web of Science ®Google Scholar
• ManganelliPFiettaPQuainiFHematologic manifestations of primary Sjögren’s syndromeClin Exp Rheumatol200624443844816956437
   PubMed Web of Science ®Google Scholar
• ZintzarasEVoulgarelisMMoutsopoulosHMThe risk of lymphoma development in autoimmune diseases: a meta-analysisArch Intern Med2005165202337234416287762
   PubMedGoogle Scholar
• NocturneGMarietteXSjögren Syndrome-associated lymphomas: an update on pathogenesis and managementBr J Haematol2015168331732725316606
   PubMed Web of Science ®Google Scholar
• WangSSVajdicCMLinetMSAssociations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL lociAm J Epidemiol2015181640642125713336
   PubMed Web of Science ®Google Scholar
• StarrAGCaimiPFFuPDual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomesBri J Haematol20161733404412
   PubMed Web of Science ®Google Scholar
• ZuccaECopie-BergmanCRicardiUGastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201324Suppl 6vi144vi14824078657
   PubMed Web of Science ®Google Scholar
• ZinzaniPLThe many faces of marginal zone lymphomaHematol Am Soc Hematol Educ Program20122012426432
   PubMed Web of Science ®Google Scholar
• ZuccaEConconiAPedrinisENongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissueBlood200310172489249512456507
   PubMed Web of Science ®Google Scholar
• ThieblemontCBastionYBergerFMucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patientsJ Clin Oncol1997154162416309193362
   PubMed Web of Science ®Google Scholar
• RadererMWöhrerSStreubelBAssessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experienceJ Clin Oncol200624193136314116769982
   PubMed Web of Science ®Google Scholar
• de BoerJPHiddinkRFRadererMDissemination patterns in non-gastric MALT lymphomaHaematologica200893220120618223283
   PubMed Web of Science ®Google Scholar
• BoveriEArcainiLMerliMBone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patientsAnn Oncol2009201129136
   PubMed Web of Science ®Google Scholar
• ArmitageJOWeisenburgerDDNew approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification ProjectJ Clin Oncol1998168278027959704731
   PubMed Web of Science ®Google Scholar
• LiuLWangHChenYRustveldLLiuGDuXLSplenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United StatesLeuk Lymphoma20135471380138623101590
   PubMed Web of Science ®Google Scholar
• ThieblemontCFelmanPBergerFTreatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patientsClin Lymphoma200231414712141954
   PubMedGoogle Scholar
• ArcainiLLazzarinoMColomboNSplenic marginal zone lymphoma: a prognostic model for clinical useBlood2006107124643464916493005
   PubMed Web of Science ®Google Scholar
• ArcainiLPaulliMBoveriESplenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profilesCancer2004100110711514692030
   PubMed Web of Science ®Google Scholar
• StarrAGCaimiPFFuPSplenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab eraHematology201722740541128105889
   PubMed Web of Science ®Google Scholar
• Parry-JonesNMatutesEGruszka-WestwoodAMSwansburyGJWotherspoonACCatovskyDPrognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patientsBr J Haematol2003120575976412614206
   PubMed Web of Science ®Google Scholar
• MatutesEOscierDMontalbanCSplenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteriaLeukemia200822348749518094718
   PubMed Web of Science ®Google Scholar
• PonzoniMKanellisGPouliouEBone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?Am J Surg Pathol201236111609161823073320
   PubMed Web of Science ®Google Scholar
• ArcainiLLucioniMBoveriEPaulliMNodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous diseaseEur J Haematol200983316517419548917
   PubMed Web of Science ®Google Scholar
• ThieblemontCMolinaTDaviFOptimizing therapy for nodal marginal zone lymphomaBlood2016127172064207126989202
   PubMed Web of Science ®Google Scholar
• ArcainiLPaulliMBurcheriSPrimary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare diseaseBr J Haematol2007136230130417233821
   PubMed Web of Science ®Google Scholar
• van den BrandMvan der VeldenWJDietsIJClinical features of patients with nodal marginal zone lymphoma compared to follicular lymphoma: similar presentation, but differences in prognostic factors and rate of transformationLeuk Lymphoma20165771649165626694256
   PubMed Web of Science ®Google Scholar
• StarrAGCaimiPFFuPDual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab eraBr J Haematol2016175227528027443247
   PubMed Web of Science ®Google Scholar
• VallisaDBernuzziPArcainiLRole of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experienceJ Clin Oncol200523346847315659492
   PubMed Web of Science ®Google Scholar
• DreylingMThieblemontCGallaminiAESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphomaAnn Oncol201324485787723425945
   PubMed Web of Science ®Google Scholar
• VannataBZuccaEHepatitis C virus-associated B-cell non-Hodgkin lymphomasHematology Am Soc Hematol Educ Program20142014159059825696916
   PubMedGoogle Scholar
• MichotJMCanioniDDrissHAntiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C studyAm J Hematol201590319720325417909
   PubMed Web of Science ®Google Scholar
• ArcainiLBessonCPeveling-OberhagJAnti-lymphoma activity of interferon-free antiviral treatment in patients with indolent B-cell lymphomas associated with hepatitis C virus infection. In: Besson C, editor. Vol 126Blood Ame Soc Hematol20151263938
   Google Scholar
• TarellaCArcainiLBaldiniLItalian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)Clin Lymphoma Myeloma Leuk2015152758525108679
   PubMed Web of Science ®Google Scholar
• ArcainiLVallisaDRattottiSAntiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana LinfomiAnn Oncol20142571404141024799461
   PubMed Web of Science ®Google Scholar
• ZulloAHassanCCristofariFEffects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphomaClin Gastroenterol Hepatol20108210511019631287
   PubMed Web of Science ®Google Scholar
• MalfertheinerPMegraudFO’MorainCCurrent concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut200756677278117170018
   PubMed Web of Science ®Google Scholar
• CheyWDWongBCGastroenterology PPCotACoAmerican College of Gastroenterology guideline on the management of Helicobacter pylori infectionAm J Gastroenterol200710281808182517608775
   PubMed Web of Science ®Google Scholar
• FerreriAJDolcettiRDuMQOcular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapyAnn Oncol200819583584617986622
   PubMed Web of Science ®Google Scholar
• GoviSDolcettiRPonzoniMFinal results of a multicenter phase II trial with translational elements to investigate the possible infective causes of ocular adnexal marginal zone B-cell lymphoma (OAMZL) with particular reference to chlamydia species and the efficacy of doxycycline as first-line lymphoma treatment (the IELSG#27 TRIAL). In: Dolcetti R, editor. Vol 118Blood Am Soc Hematol2011118267
   Google Scholar
• ZulloAHassanCRidolaLEradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic reviewJ Clin Gastroenterol2013471082482723442842
   PubMed Web of Science ®Google Scholar
• KiesewetterBRadererMAntibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literatureBlood201312281350135723770778
   PubMed Web of Science ®Google Scholar
• LecuitMLortholaryOImmunoproliferative small intestinal disease associated with Campylobacter jejuniMed Mal Infect200535Suppl 2S56S5815978389
   PubMedGoogle Scholar
• FerreriAJGoviSPonzoniMMarginal zone lymphomas and infectious agentsSemin Cancer Biol201323643144024090976
   PubMed Web of Science ®Google Scholar
• FerreriAJGoviSPasiniEChlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trialJ Clin Oncol201230242988299422802315
   PubMed Web of Science ®Google Scholar
• ThieblemontCBergerFDumontetCMucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzedBlood200095380280610648389
   PubMed Web of Science ®Google Scholar
• YahalomJMALT lymphomas: a radiation oncology viewpointAnn Hematol200180Suppl 3B100B10511757688
   PubMedGoogle Scholar
• KochPProbstABerdelWETreatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96)J Clin Oncol200523287050705916129843
   PubMed Web of Science ®Google Scholar
• GodaJSGospodarowiczMPintilieMLong-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapyCancer2010116163815382420564130
   PubMed Web of Science ®Google Scholar
• TeckieSQiSLovieSLong-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intentInt J Radiat Oncol Biol Phys201592113013725863760
   PubMed Web of Science ®Google Scholar
• WirthAGospodarowiczMAlemanBMLong-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multicentre, International Extranodal Lymphoma Study Group studyAnn Oncol20132451344135123293112
   PubMed Web of Science ®Google Scholar
• (NCCN). NCCNNational Comprehensive Cancer Network guidelines V.2.2013: non-Hodgkin’s lymphomaNational Comprehensive Cancer Network Guidelines2013 Available from: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdfAccessed November 11, 2013
   Google Scholar
• RummelMJNiederleNMaschmeyerGBendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialLancet201338198731203121023433739
   PubMed Web of Science ®Google Scholar
• SalarADomingo-DomenechEPanizoCFirst-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trialLancet Haematol201413e104e11127029228
   PubMed Web of Science ®Google Scholar
• ZuccaEConconiAMartinelliGFinal results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapyJ Clin Oncol201735171905191228355112
   PubMed Web of Science ®Google Scholar
• ThieblemontCFelmanPCallet-BauchuESplenic marginal-zone lymphoma: a distinct clinical and pathological entityLancet Oncol2003429510312573351
   PubMed Web of Science ®Google Scholar
• ChacónJIMollejoMMuñozESplenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patientsBlood200210051648165412176884
   PubMed Web of Science ®Google Scholar
• OlszewskiAJSurvival outcomes with and without splenectomy in splenic marginal zone lymphomaAm J Hematol20128711E119E12222887176
   PubMed Web of Science ®Google Scholar
• KalpadakisCPangalisGAAngelopoulouMKTreatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomyOncologist201318219019723345547
   PubMed Web of Science ®Google Scholar
• LefrèreFHermineOBelangerCFludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytesLeukemia200014457357510764141
   PubMed Web of Science ®Google Scholar
• KalpadakisCPangalisGADimopoulouMNRituximab monotherapy is highly effective in splenic marginal zone lymphomaHematol Oncol200725312713117514771
   PubMed Web of Science ®Google Scholar
• ArcainiLOrlandiEScottiMCombination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphomaClin Lymphoma20044425025215072617
   PubMedGoogle Scholar
• IannittoELuminariSTripodoCRituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II studyLeuk Lymphoma201556123281328725791121
   PubMed Web of Science ®Google Scholar
• LengletJTraulléCMounierNLong-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatmentLeuk Lymphoma20145581854186024206091
   PubMed Web of Science ®Google Scholar
• TroussardXValensiFDuchayneESplenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d’Hématologie Cellulaire (GFHC)Br J Haematol19969337317368652403
   PubMed Web of Science ®Google Scholar
• BennettMSchechterGPTreatment of splenic marginal zone lymphoma: splenectomy versus rituximabSemin Hematol201047214314720350661
   PubMed Web of Science ®Google Scholar
• KalpadakisCPangalisGAVassilakopoulosTPSachanasSAngelopoulouMKTreatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Leuk Lymphoma20145571463147024050506
   PubMed Web of Science ®Google Scholar
• BennettMYegenaSDaveHPSchechterGPRe: rituximab monotherapy is highly effective in splenic marginal zone lymphomaHematol Oncol200826211418271062
   PubMed Web of Science ®Google Scholar
• ElseMMarín-NieblaAde la CruzFRituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphomaBr J Haematol2012159332232823016878
   PubMed Web of Science ®Google Scholar
• BrownJRFriedbergJWFengYA phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomasBr J Haematol2009145674174819344412
   PubMed Web of Science ®Google Scholar
• CervettiGGalimbertiSSordiESignificant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)Ann Oncol201021485185419825880
   PubMed Web of Science ®Google Scholar
• OrciuoloEBudaGSordiE2CdA chemotherapy and rituximab in the treatment of marginal zone lymphomaLeuk Res201034218418919414190
   PubMed Web of Science ®Google Scholar
• LaribiKTempesculAGhnayaHThe bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphomaHematol Oncol201635453654127443419
   PubMed Web of Science ®Google Scholar
• ThieblemontCCoiffierBManagement of marginal zone lymphomasCurr Treat Options Oncol20067321322216615877
   PubMedGoogle Scholar
• AviviIArcainiLFerrettiVHigh dose therapy and autologous stem cell transplantation in marginal zone lymphoma: an EBMT-FIL-gimeto retrospective studyBlood20141242526
   Web of Science ®Google Scholar
• BertoniFCoiffierBSallesGMALT lymphomas: pathogenesis can drive treatmentOncology (Williston Park)2011251211341142114722229204
   PubMed Web of Science ®Google Scholar
• LiLBiermanPVoseJLoberizaFArmitageJOBociekRGHigh-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphomaClin Lymphoma Myeloma Leuk201111325325621658651
   PubMed Web of Science ®Google Scholar
• BrownJRGaudetGFriedbergJWAutologous bone marrow transplantation for marginal zone non-Hodgkin’s lymphomaLeuk Lymphoma200445231532015101717
   PubMed Web of Science ®Google Scholar
• LockeFLNeelapuSSBartlettNLClinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)J Clin Oncol20173515 Suppl7512
   Google Scholar
• GilLKazmierczakMKroll-BalcerzakRKomarnickiMBendamustine-based therapy as first-line treatment for non-Hodgkin lymphomaMed Oncol201431594424752517
   PubMed Web of Science ®Google Scholar
• KiesewetterBMayerhoeferMELukasJZielinskiCCMüllauerLRadererMRituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)Ann Hematol201493224925323925930
   PubMed Web of Science ®Google Scholar
• ConconiAMartinelliGLopez-GuillermoAClinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)Ann Oncol201122368969520810546
   PubMed Web of Science ®Google Scholar
• de VosSGoyADakhilSRMulticenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphomaJ Clin Oncol200927305023503019770386
   PubMed Web of Science ®Google Scholar
• KiesewetterBWillenbacherEWillenbacherWA phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)Blood2017129338338527879257
   PubMed Web of Science ®Google Scholar
• KalpadakisCPangalisGAAngelopoulouMKVassilakopoulosTPTreatment of splenic marginal zone lymphomaBest Pract Res Clin Haematol2017301–213914828288709
   PubMed Web of Science ®Google Scholar
• BennettMSharmaKYegenaSGavishIDaveHPSchechterGPRituximab monotherapy for splenic marginal zone lymphomaHaematologica200590685685815951303
   PubMed Web of Science ®Google Scholar
• FlinnIWvan der JagtRKahlBSRandomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT studyBlood2014123192944295224591201
   PubMed Web of Science ®Google Scholar
• TrochMJonakCMüllauerLA phase II study of bortezomib in patients with MALT lymphomaHaematologica200994573874219336742
   PubMed Web of Science ®Google Scholar
• O’ConnorOAWrightJMoskowitzCPhase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol200523467668415613699
   PubMed Web of Science ®Google Scholar
• ZuccaEBertoniFThe spectrum of MALT lymphoma at different sites: biological and therapeutic relevanceBlood2016127172082209226989205
   PubMed Web of Science ®Google Scholar
• ThieblemontCCascioneLConconiAA MALT lymphoma prognostic indexBlood2017130121409141728720586
   PubMed Web of Science ®Google Scholar
• BertoniFZuccaEState-of-the-art therapeutics: marginal-zone lymphomaJ Clin Oncol200523266415642016155028
   PubMed Web of Science ®Google Scholar
• MontalbánCAbrairaVArcainiLRisk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 casesBr J Haematol2012159216417122924582
   PubMed Web of Science ®Google Scholar
• MontalbanCAbrairaVArcainiLSimplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical useLeuk Lymphoma201455492993123799931
   PubMed Web of Science ®Google Scholar
• Kuper-HommelMJvan de SchansSAVreugdenhilGvan KriekenJHCoeberghJWTrends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sitesLeuk Lymphoma20135491891189723302044
   PubMed Web of Science ®Google Scholar
• BergerFFelmanPThieblemontCNon-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patientsBlood20009561950195610706860
   PubMed Web of Science ®Google Scholar
• HeilgeistAMcClanahanFHoADWitzens-HarigMPrognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patientsCancer201311919910622736411
   PubMed Web of Science ®Google Scholar
• BernardSDangladeDGardanoLInhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphomaInt J Cancer2015136122761277425388373
   PubMed Web of Science ®Google Scholar
• de GorterDJBeulingEAKersseboomRBruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homingImmunity20072619310417239630
   PubMed Web of Science ®Google Scholar
• de RooijMFKuilAGeestCRThe clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood2012119112590259422279054
   PubMed Web of Science ®Google Scholar
• PonaderSChenSSBuggyJJThe Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood201211951182118922180443
   PubMed Web of Science ®Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol2013311889423045577
   PubMed Web of Science ®Google Scholar
• BartlettNLCostelloBALaPlantBRSingle-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trialBlood2017131218219029074501
   PubMed Web of Science ®Google Scholar
• FowlerNNastoupilLde VosSIbrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 studyBlood201512623470
   Web of Science ®Google Scholar
• FowlerNHA phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma. In: Hiddemann W, editors. Vol 32. 2014 ASCO Annual MeetingJ Clin Oncol201432
   PubMed Web of Science ®Google Scholar
• GoedeVFischerKBuschRObinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsN Engl J Med2014370121101111024401022
   PubMed Web of Science ®Google Scholar
• SehnLHChuaNMayerJObinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trialLancet Oncol20161781081109327345636
   PubMed Web of Science ®Google Scholar
• HeroldMHosterEJanssensAImmunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised gallium trial with previously untreated marginal zone lymphoma (MZL)Hematol Oncol201735146147
   Google Scholar